Literature DB >> 16585179

Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death.

C Annette Hollmann1, Trevor Owens, Josephine Nalbantoglu, Thomas J Hudson, Robert Sladek.   

Abstract

CD40 promotes survival, proliferation, and differentiation of normal B cells but can cause activation-induced cell death in malignant B lymphocytes. CD40 ligand and anti-CD40 antibodies have been used successfully to induce apoptosis in lymphoma lines both in vitro and in xenograft tumor models. Although this makes CD40 an attractive target for antitumor therapies, the response of malignant B cells to CD40 signaling is variable, and CD40 stimulation can enhance proliferation and can increase chemoresistance in some cell lines. It would therefore be useful to identify markers that predict whether a specific cell line or tumor will undergo apoptosis when stimulated with CD40 and to identify targets downstream of CD40 that affect only the apoptotic arm of CD40 signaling. We have analyzed gene expression patterns in CD40-sensitive and CD40-resistant diffuse large B-cell lymphoma (DLBCL) cell lines to identify signaling pathways that are involved in CD40-mediated apoptosis. CD40-resistant lines expressed pre-B-cell markers, including RAG and VPREB, whereas CD40-sensitive cells resembled mature B cells and expressed higher levels of transcripts encoding several members of the CD40 signaling pathway, including LCK and VAV. In addition, CD40-sensitive DLBCL cell lines also displayed constitutive activation of extracellular signal-regulated kinase (ERK) and failed to undergo apoptosis when ERK phosphorylation was inhibited. In contrast, CD40-resistant lines showed no constitutive activation of ERK and no increase in ERK activity in response to CD40 stimulation. Our results suggest that constitutive activation of ERK may be required for death signaling by CD40.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585179     DOI: 10.1158/0008-5472.CAN-05-2498

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Authors:  G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

2.  17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

Authors:  Erin Hertlein; Amy J Wagner; Jeffrey Jones; Thomas S Lin; Kami J Maddocks; William H Towns; Virginia M Goettl; Xiaoli Zhang; David Jarjoura; Chelsey A Raymond; Derek A West; Carlo M Croce; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

3.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

4.  CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.

Authors:  Nicholas F Kuhn; Terence J Purdon; Dayenne G van Leeuwen; Andrea V Lopez; Kevin J Curran; Anthony F Daniyan; Renier J Brentjens
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

5.  The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.

Authors:  Ana Ortega-Molina; Isaac W Boss; Andres Canela; Heng Pan; Yanwen Jiang; Chunying Zhao; Man Jiang; Deqing Hu; Xabier Agirre; Itamar Niesvizky; Ji-Eun Lee; Hua-Tang Chen; Daisuke Ennishi; David W Scott; Anja Mottok; Christoffer Hother; Shichong Liu; Xing-Jun Cao; Wayne Tam; Rita Shaknovich; Benjamin A Garcia; Randy D Gascoyne; Kai Ge; Ali Shilatifard; Olivier Elemento; Andre Nussenzweig; Ari M Melnick; Hans-Guido Wendel
Journal:  Nat Med       Date:  2015-09-14       Impact factor: 53.440

6.  Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.

Authors:  Boonsil Jang; Ji-Ae Shin; Yong-Soo Kim; Ji-Young Kim; Ho-Keun Yi; Il-Song Park; Nam-Pyo Cho; Sung-Dae Cho
Journal:  Cell Oncol (Dordr)       Date:  2015-11-18       Impact factor: 6.730

7.  The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.

Authors:  Mei-Jen Chuang; Sheng-Tang Wu; Shou-Hung Tang; Xiang-Me Lai; Hsiao-Chu Lai; Kai-Hsiang Hsu; Kuang-Hui Sun; Guang-Huan Sun; Sun-Yran Chang; Dah-Shyong Yu; Pei-Wen Hsiao; Shih-Ming Huang; Tai-Lung Cha
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

8.  Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).

Authors:  Manikhandan A V Mudaliar; Ross D Haggart; Gino Miele; Grant Sellar; Karen A L Tan; John R Goodlad; Elspeth Milne; David M Vail; Ilene Kurzman; Daniel Crowther; David J Argyle
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

9.  Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.

Authors:  Nikola A Bowden; Katie A Ashton; Ricardo E Vilain; Kelly A Avery-Kiejda; Ryan J Davey; Heather C Murray; Timothy Budden; Stephen G Braye; Xu Dong Zhang; Peter Hersey; Rodney J Scott
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition.

Authors:  Mutsumi Hayashi; Hiroko Madokoro; Koji Yamada; Hiroko Nishida; Chikao Morimoto; Michiie Sakamoto; Taketo Yamada
Journal:  Cancer Cell Int       Date:  2016-04-30       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.